Shares

38 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2023

BUY
$13.37 - $17.79 $231,220 - $307,660
17,294 New
17,294 $281,000
Q1 2022

May 09, 2022

SELL
$13.37 - $17.79 $231,220 - $307,660
-17,294 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$14.28 - $19.53 $246,958 - $337,751
17,294 New
17,294 $282,000
Q3 2021

Nov 14, 2022

BUY
$12.99 - $20.47 $224,649 - $354,008
17,294 New
17,294 $257,000
Q3 2021

Nov 05, 2021

SELL
$12.99 - $20.47 $1.66 Million - $2.62 Million
-128,071 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$15.46 - $24.5 $1.98 Million - $3.14 Million
128,071 New
128,071 $2.56 Million
Q2 2021

Aug 10, 2021

SELL
$15.46 - $24.5 $1.53 Million - $2.43 Million
-99,035 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$19.33 - $37.75 $1.91 Million - $3.74 Million
99,035 New
99,035 $2.29 Million
Q1 2021

May 07, 2021

SELL
$19.33 - $37.75 $3.74 Million - $7.31 Million
-193,621 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$24.48 - $42.47 $4.74 Million - $8.22 Million
193,621 New
193,621 $4.78 Million
Q4 2020

Feb 10, 2021

SELL
$24.48 - $42.47 $4.2 Million - $7.29 Million
-171,545 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$39.09 - $53.44 $6.71 Million - $9.17 Million
171,545 New
171,545 $7.11 Million
Q3 2020

Nov 10, 2020

SELL
$39.09 - $53.44 $9.72 Million - $13.3 Million
-248,708 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$46.7 - $92.04 $11.6 Million - $22.9 Million
248,708 New
248,708 $11.9 Million
Q2 2020

Aug 07, 2020

SELL
$46.7 - $92.04 $15 Million - $29.5 Million
-320,216 Closed
0 $0
Q1 2020

May 07, 2021

BUY
$48.35 - $118.68 $15.5 Million - $38 Million
320,216 New
320,216 $20.2 Million
Q1 2020

May 08, 2020

SELL
$48.35 - $118.68 $14.6 Million - $35.8 Million
-301,988 Closed
0 $0
Q4 2019

Mar 03, 2020

BUY
$57.36 - $124.1 $17.3 Million - $37.5 Million
301,988 New
301,988 $37.4 Million
Q4 2019

Feb 12, 2020

SELL
$57.36 - $124.1 $17.3 Million - $37.5 Million
-301,988 Closed
0 $0
Q3 2019

Nov 13, 2020

BUY
$58.69 - $80.46 $17.7 Million - $24.3 Million
301,988 New
301,988 $20 Million
Q3 2019

Nov 08, 2019

SELL
$58.69 - $80.46 $17.7 Million - $24.3 Million
-301,988 Closed
0 $0
Q2 2019

Aug 13, 2020

BUY
$77.77 - $120.68 $23.5 Million - $36.4 Million
301,988 New
301,988 $24 Million
Q2 2019

Aug 09, 2019

SELL
$77.77 - $120.68 $21.9 Million - $34 Million
-282,045 Closed
0 $0
Q4 2018

Mar 04, 2019

BUY
$85.79 - $126.46 $24.2 Million - $35.7 Million
282,045 New
282,045 $28.4 Million
Q4 2018

Feb 08, 2019

SELL
$85.79 - $126.46 $24.2 Million - $35.7 Million
-282,045 Closed
0 $0
Q3 2018

Nov 12, 2019

BUY
$88.49 - $127.55 $25 Million - $36 Million
282,045 New
282,045 $35.6 Million
Q3 2018

Nov 09, 2018

SELL
$88.49 - $127.55 $16.6 Million - $23.9 Million
-187,769 Closed
0 $0
Q2 2018

Aug 12, 2019

BUY
$60.0 - $85.67 $11.3 Million - $16.1 Million
187,769 New
187,769 $15.8 Million
Q2 2018

Jul 23, 2018

SELL
$60.0 - $85.67 $2.06 Million - $2.94 Million
-34,265 Closed
0 $0
Q1 2018

May 15, 2019

BUY
$52.72 - $67.25 $1.81 Million - $2.3 Million
34,265 New
34,265 $2.11 Million
Q1 2018

May 09, 2018

SELL
$52.72 - $67.25 $846,946 - $1.08 Million
-16,065 Closed
0 $0
Q4 2017

Mar 05, 2018

BUY
$58.2 - $72.76 $934,983 - $1.17 Million
16,065 New
16,065 $939,000
Q4 2017

Feb 09, 2018

SELL
$58.2 - $72.76 $934,983 - $1.17 Million
-16,065 Closed
0 $0
Q3 2017

Nov 13, 2018

BUY
$57.01 - $118.75 $915,865 - $1.91 Million
16,065 New
16,065 $932,000
Q3 2017

Nov 07, 2017

SELL
$57.01 - $118.75 $316,804 - $659,893
-5,557 Closed
0 $0
Q2 2017

Jul 24, 2018

SELL
N/A
-66,324 Reduced 92.27%
5,557 $673,000
Q1 2017

May 11, 2018

SELL
N/A
-69,486 Reduced 49.15%
71,881 $8.13 Million
Q3 2016

Nov 13, 2017

BUY
N/A
141,367
141,367 $0

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.